市場調査レポート
商品コード
1295490

デジタルパソロジーの世界市場:製品別 (スキャナー、ソフトウェア、ストレージシステム)・種類別 (人体、動物)・用途別 (遠隔医療、トレーニング、疾病診断、創薬)・エンドユーザー別 (製薬・バイオテクノロジー、学術機関、病院) の将来予測 (2028年まで)

Digital Pathology Market by Product (Scanner, Software, Storage System), Type (Human, Veterinary), Application (Teleconsulation, Training, Disease Diagnosis, Drug Discovery), End User (Pharma & Biotech, Academia, Hospitals) - Global Forecast to 2028

出版日: | 発行: MarketsandMarkets | ページ情報: 英文 265 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=160.11円
デジタルパソロジーの世界市場:製品別 (スキャナー、ソフトウェア、ストレージシステム)・種類別 (人体、動物)・用途別 (遠隔医療、トレーニング、疾病診断、創薬)・エンドユーザー別 (製薬・バイオテクノロジー、学術機関、病院) の将来予測 (2028年まで)
出版日: 2023年06月15日
発行: MarketsandMarkets
ページ情報: 英文 265 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界のデジタルパソロジーの市場規模は、予測期間中に13.6%のCAGRで成長し、2023年の9億米ドルから、2028年には18億米ドルに達すると予測されています。

デジタルパソロジー市場の動向は主に、医薬品開発におけるデジタルパソロジーの用途拡大、新興国における早期がん診断の認知度向上、がん検診の推奨といった要因によってもたらされます。

一方、デジタルパソロジーシステムのコストが高いため、市場の成長はある程度抑制されると予想されます。

"ソフトウェア分野が予測期間中に最も高いCAGRで成長する"

製品別に見ると、ソフトウェア分野が予測期間中に最も高いCAGRで成長すると予測されています。これは、病理医による統合型ソフトウェアの採用率の高さ、各種医療施設での遠隔一次診断向けデジタルパソロジーソフトウェアソリューションの採用増加によるものと考えられます。

"人体病理学分野が予測期間中に最も高いCAGRで成長する"

種類別では、2023年に人体病理学分野が最も高いCAGRで成長すると予測されます。その要因として、新興国におけるがんの早期診断に対する意識の高まり、学術研究機関・大学・病理検査室の協力関係の拡大などが挙げられます。

"創薬分野は予測期間中に最も高いCAGRで成長する"

用途別に見ると、2023年には創薬用途の分野が予測期間中に最も高いCAGRで成長すると予測されています。その主な要因には、ハイスループットスクリーニングとイメージング、前臨床・臨床研究数の増加が、創薬用途のセグメントの大きなシェアと高い成長率などがあります。

"製薬・バイオテクノロジー企業が予測期間中に最大のシェアを占める"

エンドユーザー別に見ると、製薬・バイオテクノロジー企業がデジタルパソロジー市場の最大エンドユーザーとなっています。2023年には、薬物毒性検査におけるデジタルパソロジーの利用拡大により、製薬・バイオテクノロジー企業のセグメントが最大の市場シェアを占めると予測されています。バイオテクノロジー企業は、バイオバンキング、バイオ医薬品研究・分子アッセイ・個別化医療の開発にデジタル病理検査を利用しています。

"地域別では、北米がデジタル病理学市場で最大のシェアを占める"

地域別では、北米が2022年に最大の市場シェアを占めました。予測期間中も同市場は最も高い成長率が見込まれています。高齢者人口の増加、がんの有病率の上昇、高品質なインフラの存在、北米における有利な償還などの要因が、北米の市場成長を促進しています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • イントロダクション
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 課題
  • 生態系市場マップ
  • 価格分析
  • 新しいIVD規制が各種市場に与える影響
  • 技術分析
  • デジタルパソロジーにおける人工知能 (AI)
  • ポーターのファイブフォース分析
  • 主要な会議とイベント (2023年~2024年)
  • 関税と規制の分析
  • 主要な利害関係者と購入基準
  • 特許分析

第6章 デジタルパソロジー市場:製品別

  • イントロダクション
  • スキャナー
    • 明視野スキャナー
    • その他のスキャナー
  • ソフトウェア
    • 統合型ソフトウェア
    • スタンドアロン型ソフトウェア
  • ストレージシステム

第7章 デジタルパソロジー市場:種類別

  • イントロダクション
  • 人体病理学
  • 動物病理学

第8章 デジタルパソロジー市場:用途別

  • イントロダクション
  • 創薬
  • 疾患診断
  • トレーニング・教育

第9章 デジタルパソロジー市場:エンドユーザー別

  • イントロダクション
  • 製薬・バイオテクノロジー企業
  • 病院・参考検査室
  • 学術研究機関

第10章 デジタルパソロジー市場:地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • スウェーデン
    • デンマーク
    • フランス
    • その他の欧州
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • その他のアジア太平洋
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他のラテンアメリカ
  • 中東・アフリカ

第11章 競合情勢

  • 概要
  • 主要企業が採用した戦略
  • 主要企業の収益シェア分析
  • 競合ベンチマーキング
  • 企業評価クアドラント:主要企業向け
  • 企業評価クアドラント:中小企業/新興企業向け
  • 市場シェア分析
  • 競合シナリオ

第12章 企業プロファイル

  • 主要企業
    • DANAHER CORPORATION
    • KONINKLIJKE PHILIPS N.V.
    • HAMAMATSU PHOTONICS K.K.
    • F. HOFFMANN-LA ROCHE LTD.
    • SECTRA AB
    • AKOYA BIOSCIENCES, INC.
    • 3DHISTECH LTD.
    • APOLLO ENTERPRISE IMAGING CORP.
    • XIFIN, INC.
    • HURON DIGITAL PATHOLOGY
    • HOLOGIC, INC.
    • CORISTA
    • INDICA LABS INC.
    • OBJECTIVE PATHOLOGY SERVICES LIMITED
    • OPTRASCAN INC.
    • GLENCOE SOFTWARE, INC.
    • AIFORIA TECHNOLOGIES OYJ
    • PAIGE AI, INC.
    • FUJIFILM HOLDINGS CORPORATION
    • PROSCIA INC.
  • その他の企業
    • PATHAI, INC.
    • KONFOONG BIOTECH INTERNATIONAL CO., LTD.
    • MIKROSCAN TECHNOLOGIES, INC.
    • MOTIC DIGITAL PATHOLOGY
    • KANTERON SYSTEMS

第13章 付録

目次
Product Code: HIT 2608

The global digital pathology market is projected to reach USD 1.8 billion by 2028 from USD 0.9 billion in 2023, at a CAGR of 13.6% during the forecast period. Growth in the digital pathology market is mainly driven by factors such as the growing applications of digital pathology in drug development , growing awareness of early cancer diagnosis in emerging economies, and recommendations for cancer screening.

On the other hand, the high costs of digital pathology systems are expected to restrain market growth to a certain extent.

Software segment is projected to grow at the highest CAGR during the forecast period By product, the global digital pathology market is segmented into scanners, software, and storage systems. The software segment is projected to grow at the highest CAGR during the forecast period.This can be attributed to the high adoption of integrated software by pathologists, and increased adoption of digital pathology software solutions in various healthcare facilities for remote primary diagnosis.

Human pathology segment is projected to grow at the highest CAGR during the forecast period By type, the digital pathology market is segmented into human pathology and veterinary pathology. In 2023, the human pathology segment is projected to grow at the highest CAGR due to the growing awareness of early cancer diagnosis in emerging economies, and growing collaborations among academic research institutes, universities, and pathology laboratories.

Drug discovery segment is projected to grow at the highest CAGR during the forecast period

By application, the digital pathology market is segmented into drug discovery, disease diagnosis, and training & education. In 2023, drug discovery application segment is projected to grow at the highest CAGR during the forecast period. The growth in high throughput screening and imaging, and the rising number of preclinical & clinical studies are the major factors responsible for the large share and high growth rate of the drug discovery application segment.

Pharmaceutical & biotechnology companies end user segment is projected to account for the largest share of the digital pathology market By end user, the digital pathology market is broadly segmented into pharmaceutical & biotechnology companies, hospitals & reference laboratories, and academic & research institutes. Pharmaceutical & biotechnology companies are the largest end users of the digital pathology market. In 2023, the pharmaceutical & biotechnology companies segment is projected to account for the largest share of the digital pathology market due to growing use of digital pathology for drug toxicology testing. Biotechnology companies use digital pathology for biobanking, biopharmaceutical studies, molecular assays, and the development of individualized medicine.

By region, North America is projected to account for the largest share of the digital pathology market

By region,North America accounted for the largest share of the digital pathology market in 2022. During the forecast period this market is expected to grow at the highest rate. Factors such as the growing geriatric population, rising prevalence of cancer, the presence of high-quality infrastructure, and the favorable reimbursement in the region are driving the growth of the market in North America.

Breakdown of supply-side primary interviews: * By Company Type: Tier 1 - 35%, Tier 2 - 45%, and Tier 3 - 20% * By Designation: C-level - 35%, Director-level - 25%, and Others - 40% * By Region: North America - 40%, Europe - 30%, APAC -20%, Latin America - 5%,Middle East & Africa-5%

Some of the prominent players operating in the digital pathology market include Danaher Corporation (US), Koninklijke Philips N.V. (Netherlands), Hamamatsu Photonics K.K. (Japan), F. Hoffmann-La Roche Ltd. (Switzerland), 3DHISTECH (Hungary), , Objective Pathology Services Limited (Canada), Sectra AB (Sweden), OptraSCAN (US), Akoya Biosciences, Inc. (US), Glencoe Software, Inc. (US), Aiforia (Finland), Paige AI, Inc. (US), Fujifilm Holdings Corporation (Japan), Apollo Enterprise Imaging (US), XIFIN, Inc. (US), Huron Digital Pathology (Canada), Hologic, Inc. (US), Corista (US), Indica Labs Inc. (US), Proscia Inc. (US), KONFOONG BIOTECH INTERNATIONAL CO., LTD. (China), Mikroscan Technologies, Inc. (US), PathAI (US), Motic Digital Pathology (US), KONFOONG BIOTECH INTERNATIONAL CO., LTD. (China), Mikroscan Technologies, Inc. (US), and Kanteron Systems (Spain).

Research Coverage

This report studies the digital pathology market based on type, application, product, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions and respective countries.

Key Benefits of Buying the Report

This report focuses on various levels of analysis-industry trends, market share of top players, and company profiles, which together form basic views and analyze the competitive landscape, and high-growth regions and their drivers, restraints, challenges, and opportunities. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the market and garner greater market shares.

This report provides insights into the following pointers:

Analysis of key drivers (increasing adoption of digital pathology to enhance lab efficiency, rising incidence of cancer, growing applications of digital pathology in drug development and companion diagnostics, growing awareness of early cancer diagnosis in emerging economies, and recommendations for cancer screening),opportunities (introduction of affordable scanners for private pathology practices, growing demand for personalized medicine, and high growth opportunities in emerging economies) and challenges (shortage of trained pathologists) influencing the growth of digital pathology market.

Market Penetration: Comprehensive information on product portfolios offered by the top players in the global digital pathology market . The report analyzes this market by product, type, application, end user, and region

Product Development/Innovation: Detailed insights on upcoming trends and product launches in the global digital pathology market

Market Development: Comprehensive information on the lucrative emerging markets by product, type, application, end user, and region

Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global digital pathology market

Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players in the global digital pathology market

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS OF STUDY
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • FIGURE 1 DIGITAL PATHOLOGY MARKET
    • 1.3.2 YEARS CONSIDERED
  • 1.4 CURRENCY
  • 1.5 STUDY LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES
    • 1.7.1 ECONOMIC RECESSION IMPACT ON DIGITAL PATHOLOGY MARKET

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH APPROACH
  • 2.2 RESEARCH DESIGN
    • FIGURE 2 RESEARCH DESIGN
    • 2.2.1 SECONDARY RESEARCH
      • 2.2.1.1 Key data from secondary sources
    • 2.2.2 PRIMARY RESEARCH
    • FIGURE 3 PRIMARY SOURCES
      • 2.2.2.1 Key data from primary sources
      • 2.2.2.2 Insights from primary experts
      • 2.2.2.3 Breakdown of primaries
    • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.3 MARKET SIZE ESTIMATION
    • FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
    • FIGURE 6 DIGITAL PATHOLOGY MARKET: REVENUE SHARE ANALYSIS ILLUSTRATION OF DANAHER CORPORATION
    • FIGURE 7 BOTTOM-UP APPROACH
    • FIGURE 8 CAGR PROJECTIONS
    • FIGURE 9 IMPACT ON MARKET GROWTH AND CAGR: ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2023-2028)
  • 2.4 DATA TRIANGULATION APPROACH
    • FIGURE 10 DATA TRIANGULATION METHODOLOGY
  • 2.5 MARKET SHARE ANALYSIS
  • 2.6 STUDY ASSUMPTIONS
  • 2.7 RISK ASSESSMENT
    • TABLE 1 RISK ASSESSMENT: DIGITAL PATHOLOGY MARKET
  • 2.8 MARKET LIMITATIONS
    • 2.8.1 METHODOLOGY-RELATED LIMITATIONS
    • 2.8.2 SCOPE-RELATED LIMITATIONS

3 EXECUTIVE SUMMARY

    • FIGURE 11 DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
    • FIGURE 12 DIGITAL PATHOLOGY MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 13 DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
    • FIGURE 14 DIGITAL PATHOLOGY MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    • FIGURE 15 GEOGRAPHICAL SNAPSHOT OF DIGITAL PATHOLOGY MARKET

4 PREMIUM INSIGHTS

  • 4.1 DIGITAL PATHOLOGY MARKET OVERVIEW
    • FIGURE 16 RISING PREVALENCE OF CANCER TO DRIVE MARKET
  • 4.2 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY END USER & COUNTRY (2022)
    • FIGURE 17 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN DIGITAL PATHOLOGY MARKET IN 2022
  • 4.3 DIGITAL PATHOLOGY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 18 UK TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
  • 4.4 REGIONAL MIX: DIGITAL PATHOLOGY MARKET (2023-2028)
    • FIGURE 19 NORTH AMERICA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD (2023-2028)
  • 4.5 DIGITAL PATHOLOGY MARKET: DEVELOPING VS. DEVELOPED MARKETS
    • FIGURE 20 DEVELOPED MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 21 DIGITAL PATHOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing adoption of digital pathology to enhance lab efficiency
      • 5.2.1.2 Rising incidence of cancer
    • FIGURE 22 GLOBAL CANCER INCIDENCE, 2008-2030
    • TABLE 2 INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
      • 5.2.1.3 Growing applications of digital pathology in drug development and companion diagnostics
      • 5.2.1.4 Growing awareness of early cancer diagnosis in emerging economies
      • 5.2.1.5 Recommendations for cancer screening
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High cost of digital pathology systems
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Introduction of affordable scanners for private pathology practices
      • 5.2.3.2 Growing demand for personalized medicine
    • TABLE 3 US: GROWTH IN NUMBER OF PERSONALIZED MEDICINES, 2008-2020
    • FIGURE 23 FDA-APPROVED PERSONALIZED MEDICINES, 2015-2021
      • 5.2.3.3 High growth opportunities in emerging economies
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Shortage of trained pathologists
    • TABLE 4 NUMBER OF INHABITANTS PER PATHOLOGIST, BY COUNTRY, 2020
  • 5.3 ECOSYSTEM MARKET MAP
    • FIGURE 24 DIGITAL PATHOLOGY MARKET: ECOSYSTEM MARKET MAP
  • 5.4 PRICING ANALYSIS
    • FIGURE 25 AVERAGE SELLING PRICE TREND OF SCANNERS, BY REGION, 2018-2025
  • 5.5 IMPACT OF NEW IVD REGULATION ON DIFFERENT MARKETS
    • FIGURE 26 TIMELINE AND TRANSITION TO NEW MDR AND IVDR
    • 5.5.1 IMPACT ON CLINICAL LAB SERVICES
    • 5.5.2 IMPACT ON IVD
    • 5.5.3 IMPACT ON DIGITAL PATHOLOGY
  • 5.6 TECHNOLOGY ANALYSIS
  • 5.7 ARTIFICIAL INTELLIGENCE (AI) IN DIGITAL PATHOLOGY
    • 5.7.1 LABEL-FREE IMAGING IN DIGITAL PATHOLOGY
    • 5.7.2 COMPUTATIONAL IMAGE ANALYSIS IN DIGITAL PATHOLOGY
  • 5.8 PORTER'S FIVE FORCES ANALYSIS
    • 5.8.1 THREAT OF NEW ENTRANTS
    • 5.8.2 THREAT OF SUBSTITUTES
    • 5.8.3 BARGAINING POWER OF SUPPLIERS
    • 5.8.4 BARGAINING POWER OF BUYERS
    • 5.8.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.9 KEY CONFERENCES & EVENTS, 2023-2024
    • TABLE 5 DIGITAL PATHOLOGY MARKET: DETAILED LIST OF CONFERENCES & EVENTS
  • 5.10 TARIFF AND REGULATORY ANALYSIS
    • 5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 6 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.10.2 REGULATORY ANALYSIS
      • 5.10.2.1 North America
        • 5.10.2.1.1 US
    • TABLE 7 US FDA: MEDICAL DEVICE CLASSIFICATION
    • TABLE 8 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
        • 5.10.2.1.2 Canada
    • TABLE 9 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
      • 5.10.2.2 Europe
    • TABLE 10 EUROPE: CLASSIFICATION OF IVD DEVICES
    • FIGURE 27 EUROPE: IVDR TIMELINE
      • 5.10.2.3 Asia Pacific
        • 5.10.2.3.1 Japan
    • TABLE 11 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA
        • 5.10.2.3.2 China
    • TABLE 12 CHINA: CLASSIFICATION OF MEDICAL DEVICES
        • 5.10.2.3.3 India
  • 5.11 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF DIGITAL PATHOLOGY PRODUCTS
    • TABLE 13 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF DIGITAL PATHOLOGY PRODUCTS (%)
    • 5.11.2 BUYING CRITERIA
    • FIGURE 29 KEY BUYING CRITERIA FOR DIGITAL PATHOLOGY PRODUCTS
    • TABLE 14 KEY BUYING CRITERIA FOR DIGITAL PATHOLOGY PRODUCTS
  • 5.12 PATENT ANALYSIS
    • 5.12.1 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
    • FIGURE 30 TOP PATENT OWNERS AND APPLICANTS: DIGITAL PATHOLOGY MARKET (JANUARY 2011-FEBRUARY 2023)
    • FIGURE 31 TOP APPLICANT JURISDICTIONS FOR DIGITAL PATHOLOGY MARKET (JANUARY 2011-FEBRUARY 2023)
    • 5.12.2 PATENT PUBLICATION TRENDS FOR DIGITAL PATHOLOGY MARKET
    • FIGURE 32 PATENT ANALYSIS: DIGITAL PATHOLOGY MARKET (JANUARY 2011-FEBRUARY 2023)
    • TABLE 15 LIST OF PATENTS/PATENT APPLICATIONS IN DIGITAL PATHOLOGY MARKET, 2020-2023

6 DIGITAL PATHOLOGY MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
    • TABLE 16 DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • 6.2 SCANNERS
    • TABLE 17 SCANNING MAGNIFICATION AND APPLICATIONS
    • TABLE 18 DIGITAL PATHOLOGY SCANNERS OFFERED BY KEY MARKET PLAYERS
    • TABLE 19 DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 20 DIGITAL PATHOLOGY SCANNERS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • 6.2.1 BRIGHTFIELD SCANNERS
      • 6.2.1.1 Ideal solutions for small laboratories
    • TABLE 21 BRIGHTFIELD SCANNERS OFFERED BY KEY MARKET PLAYERS
    • TABLE 22 BRIGHTFIELD SCANNERS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • 6.2.2 OTHER SCANNERS
    • TABLE 23 OTHER SCANNERS OFFERED BY KEY MARKET PLAYERS
    • TABLE 24 OTHER SCANNERS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.3 SOFTWARE
    • TABLE 25 DIGITAL PATHOLOGY SOFTWARE OFFERED BY KEY MARKET PLAYERS
    • TABLE 26 DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 27 DIGITAL PATHOLOGY SOFTWARE MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • 6.3.1 INTEGRATED SOFTWARE
      • 6.3.1.1 Includes various modules for different digital pathology applications
    • TABLE 28 INTEGRATED SOFTWARE OFFERED BY KEY MARKET PLAYERS
    • TABLE 29 INTEGRATED SOFTWARE MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • 6.3.2 STANDALONE SOFTWARE
    • TABLE 30 STANDALONE SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 31 STANDALONE SOFTWARE MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
      • 6.3.2.1 Information management software
        • 6.3.2.1.1 Enables comprehensive integration with information systems of any institute
    • TABLE 32 INFORMATION MANAGEMENT SOFTWARE OFFERED BY KEY MARKET PLAYERS
    • TABLE 33 INFORMATION MANAGEMENT SOFTWARE MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
      • 6.3.2.2 Image analysis software
        • 6.3.2.2.1 Provides easy-to-use solutions for quantitative evaluation of brightfield slides
    • TABLE 34 IMAGE ANALYSIS SOFTWARE OFFERED BY KEY MARKET PLAYERS
    • TABLE 35 IMAGE ANALYSIS SOFTWARE MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.4 STORAGE SYSTEMS
    • 6.4.1 NEED FOR SAFE AND RELIABLE STORAGE OF HIGH-QUALITY IMAGES TO DRIVE MARKET
    • TABLE 36 STORAGE SYSTEMS OFFERED BY KEY MARKET PLAYERS
    • TABLE 37 STORAGE SYSTEMS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)

7 DIGITAL PATHOLOGY MARKET, BY TYPE

  • 7.1 INTRODUCTION
    • TABLE 38 DIGITAL PATHOLOGY MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • 7.2 HUMAN PATHOLOGY
    • 7.2.1 INCREASING CANCER RESEARCH ACTIVITIES TO DRIVE MARKET
    • TABLE 39 HUMAN DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.3 VETERINARY PATHOLOGY
    • 7.3.1 REDUCTION IN TURNAROUND TIME FOR ANIMAL DISEASE DIAGNOSIS TO DRIVE MARKET
    • TABLE 40 VETERINARY DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)

8 DIGITAL PATHOLOGY MARKET, BY APPLICATION

  • 8.1 INTRODUCTION
    • TABLE 41 DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 42 PRODUCT CROSS-MAPPING FOR DIFFERENT APPLICATIONS
  • 8.2 DRUG DISCOVERY
    • 8.2.1 LARGEST AND FASTEST-GROWING SEGMENT OF MARKET
    • TABLE 43 APPLICATIONS OF DIGITAL PATHOLOGY IN DRUG DISCOVERY
    • TABLE 44 DIGITAL PATHOLOGY MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.3 DISEASE DIAGNOSIS
    • 8.3.1 USE OF ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN DIGITAL PATHOLOGY SOLUTIONS TO PROPEL MARKET
    • TABLE 45 DIGITAL PATHOLOGY MARKET FOR DISEASE DIAGNOSIS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.4 TRAINING & EDUCATION
    • 8.4.1 DIGITAL PATHOLOGY CAN IMPROVE EDUCATION & TRAINING PROVIDED TO PATHOLOGISTS IN ACADEMIC INSTITUTES
    • TABLE 46 DIGITAL PATHOLOGY MARKET FOR TRAINING & EDUCATION, BY COUNTRY, 2021-2028 (USD MILLION)

9 DIGITAL PATHOLOGY MARKET, BY END USER

  • 9.1 INTRODUCTION
    • TABLE 47 DIGITAL PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • TABLE 48 PRODUCT CROSS-MAPPING FOR DIFFERENT END USERS
  • 9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 9.2.1 RISING USE OF DIGITAL PATHOLOGY IN DRUG DEVELOPMENT TO DRIVE MARKET
    • TABLE 49 DIGITAL PATHOLOGY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.3 HOSPITALS & REFERENCE LABORATORIES
    • 9.3.1 INCREASING INCIDENCE OF INFECTIOUS DISEASES TO DRIVE MARKET
    • TABLE 50 HOSPITAL DEPLOYMENT OF DIGITAL PATHOLOGY SOLUTIONS
    • TABLE 51 DIGITAL PATHOLOGY MARKET FOR HOSPITALS & REFERENCE LABORATORIES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.4 ACADEMIC & RESEARCH INSTITUTES
    • 9.4.1 INCREASING INVESTMENTS FOR RESEARCH IN DISEASE DIAGNOSIS TO SUPPORT MARKET GROWTH
    • TABLE 52 DIGITAL PATHOLOGY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)

10 DIGITAL PATHOLOGY MARKET, BY REGION

  • 10.1 INTRODUCTION
    • FIGURE 33 DIGITAL PATHOLOGY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • TABLE 53 DIGITAL PATHOLOGY MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 10.2 NORTH AMERICA
    • 10.2.1 IMPACT OF RECESSION ON NORTH AMERICAN DIGITAL PATHOLOGY MARKET
    • FIGURE 34 NORTH AMERICA: DIGITAL PATHOLOGY MARKET SNAPSHOT
    • TABLE 54 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 55 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 56 NORTH AMERICA: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 57 NORTH AMERICA: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 58 NORTH AMERICA: STANDALONE SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 59 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 60 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 61 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.2.2 US
      • 10.2.2.1 Rapidly increasing geriatric population and growing prevalence of chronic diseases to drive market
    • TABLE 62 US: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
    • TABLE 63 US: KEY MACROINDICATORS
    • TABLE 64 US: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 65 US: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 66 US: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 67 US: STANDALONE SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 68 US: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 69 US: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 70 US: DIGITAL PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.2.3 CANADA
      • 10.2.3.1 Increasing government initiatives for cancer awareness to drive market growth
    • TABLE 71 CANADA: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
    • TABLE 72 CANADA: DIGITAL PATHOLOGY INITIATIVES AND FUNDING
    • TABLE 73 CANADA: KEY MACROINDICATORS
    • TABLE 74 CANADA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 75 CANADA: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 76 CANADA: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 77 CANADA: STANDALONE SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 78 CANADA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 79 CANADA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 80 CANADA: DIGITAL PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.3 EUROPE
    • 10.3.1 IMPACT OF RECESSION ON EUROPEAN DIGITAL PATHOLOGY MARKET
    • TABLE 81 EUROPE: DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 82 EUROPE: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 83 EUROPE: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 84 EUROPE: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 85 EUROPE: STANDALONE SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 86 EUROPE: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 87 EUROPE: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 88 EUROPE: DIGITAL PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.2 UK
      • 10.3.2.1 Rising government funding and initiatives to drive market
    • TABLE 89 UK: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
    • TABLE 90 UK: KEY MACROINDICATORS
    • TABLE 91 UK: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 92 UK: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 93 UK: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 94 UK: STANDALONE SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 95 UK: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 96 UK: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 97 UK: DIGITAL PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.3 GERMANY
      • 10.3.3.1 High healthcare expenditure and supportive research initiatives to drive market
    • TABLE 98 GERMANY: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
    • TABLE 99 GERMANY: KEY MACROINDICATORS
    • TABLE 100 GERMANY: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 101 GERMANY: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 102 GERMANY: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 103 GERMANY: STANDALONE SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 104 GERMANY: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 105 GERMANY: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 106 GERMANY: DIGITAL PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.4 SWEDEN
      • 10.3.4.1 Increasing prevalence of chronic diseases to support market growth
    • TABLE 107 SWEDEN: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
    • TABLE 108 SWEDEN: KEY MACROINDICATORS
    • TABLE 109 SWEDEN: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 110 SWEDEN: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 111 SWEDEN: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 112 SWEDEN: STANDALONE SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 113 SWEDEN: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 114 SWEDEN: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 115 SWEDEN: DIGITAL PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.5 DENMARK
      • 10.3.5.1 Increasing deployment of digital pathology solutions to support market growth
    • TABLE 116 DENMARK: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
    • TABLE 117 DENMARK: KEY MACROINDICATORS
    • TABLE 118 DENMARK: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 119 DENMARK: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 120 DENMARK: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 121 DENMARK: STANDALONE SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 122 DENMARK: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 123 DENMARK: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 124 DENMARK: DIGITAL PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.6 FRANCE
      • 10.3.6.1 Increasing government funding and favorable insurance system to drive adoption
    • TABLE 125 FRANCE: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
    • TABLE 126 FRANCE: KEY MACROINDICATORS
    • TABLE 127 FRANCE: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 128 FRANCE: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 129 FRANCE: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 130 FRANCE: STANDALONE SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 131 FRANCE: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 132 FRANCE: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 133 FRANCE: DIGITAL PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.7 REST OF EUROPE
    • TABLE 134 REST OF EUROPE: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 135 REST OF EUROPE: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 136 REST OF EUROPE: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 137 REST OF EUROPE: STANDALONE SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 138 REST OF EUROPE: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 139 REST OF EUROPE: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 140 REST OF EUROPE: DIGITAL PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.4 ASIA PACIFIC
    • 10.4.1 IMPACT OF RECESSION ON ASIA PACIFIC DIGITAL PATHOLOGY MARKET
    • FIGURE 35 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET SNAPSHOT
    • TABLE 141 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 142 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 143 ASIA PACIFIC: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 144 ASIA PACIFIC: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 145 ASIA PACIFIC: STANDALONE SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 146 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 147 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 148 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.2 CHINA
      • 10.4.2.1 Rising geriatric population to drive demand for digital pathology products
    • TABLE 149 CHINA: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
    • TABLE 150 CHINA: KEY MACROINDICATORS
    • TABLE 151 CHINA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 152 CHINA: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 153 CHINA: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 154 CHINA: STANDALONE SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 155 CHINA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 156 CHINA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 157 CHINA: DIGITAL PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.3 JAPAN
      • 10.4.3.1 Advanced healthcare infrastructure to support market growth
    • TABLE 158 JAPAN: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
    • TABLE 159 JAPAN: KEY MACROINDICATORS
    • TABLE 160 JAPAN: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 161 JAPAN: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 162 JAPAN: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 163 JAPAN: STANDALONE SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 164 JAPAN: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 165 JAPAN: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 166 JAPAN: DIGITAL PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.4 INDIA
      • 10.4.4.1 Increasing awareness regarding benefits of digital pathology solutions to drive market
    • TABLE 167 INDIA: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
    • TABLE 168 INDIA: KEY MACROINDICATORS
    • TABLE 169 INDIA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 170 INDIA: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 171 INDIA: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 172 INDIA: STANDALONE SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 173 INDIA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 174 INDIA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 175 INDIA: DIGITAL PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.5 REST OF ASIA PACIFIC
    • TABLE 176 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 177 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 178 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 179 REST OF ASIA PACIFIC: STANDALONE SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 180 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 181 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 182 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.5 LATIN AMERICA
    • 10.5.1 IMPACT OF RECESSION ON LATIN AMERICAN DIGITAL PATHOLOGY MARKET
    • TABLE 183 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 184 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 185 LATIN AMERICA: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 186 LATIN AMERICA: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 187 LATIN AMERICA: STANDALONE SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 188 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 189 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 190 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.5.2 BRAZIL
      • 10.5.2.1 Rising initiatives to drive adoption of digital pathology solutions
    • TABLE 191 BRAZIL: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
    • TABLE 192 BRAZIL: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 193 BRAZIL: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 194 BRAZIL: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 195 BRAZIL: STANDALONE SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 196 BRAZIL: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 197 BRAZIL: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 198 BRAZIL: DIGITAL PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.5.3 MEXICO
      • 10.5.3.1 Rising burden of cancer to drive uptake of digital pathology solutions
    • TABLE 199 MEXICO: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
    • TABLE 200 MEXICO: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 201 MEXICO: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 202 MEXICO: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 203 MEXICO: STANDALONE SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 204 MEXICO: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 205 MEXICO: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 206 MEXICO: DIGITAL PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.5.4 REST OF LATIN AMERICA
    • TABLE 207 REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 208 REST OF LATIN AMERICA: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 209 REST OF LATIN AMERICA: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 210 REST OF LATIN AMERICA: STANDALONE SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 211 REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 212 REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 213 REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.6 MIDDLE EAST & AFRICA
    • 10.6.1 INFRASTRUCTURAL DEVELOPMENTS TO SUPPORT MARKET GROWTH
    • 10.6.2 IMPACT OF RECESSION ON MIDDLE EAST & AFRICAN DIGITAL PATHOLOGY MARKET
    • TABLE 214 MIDDLE EAST AND AFRICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 215 MIDDLE EAST AND AFRICA: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 216 MIDDLE EAST AND AFRICA: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 217 MIDDLE EAST AND AFRICA: STANDALONE SOFTWARE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 218 MIDDLE EAST AND AFRICA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 219 MIDDLE EAST AND AFRICA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 220 MIDDLE EAST AND AFRICA: DIGITAL PATHOLOGY MARKET, BY END USER, 2021-2028 (USD MILLION)

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 STRATEGIES ADOPTED BY KEY PLAYERS
    • FIGURE 36 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN DIGITAL PATHOLOGY MARKET
  • 11.3 REVENUE SHARE ANALYSIS OF KEY MARKET PLAYERS
    • FIGURE 37 REVENUE ANALYSIS OF KEY PLAYERS IN DIGITAL PATHOLOGY MARKET
  • 11.4 COMPETITIVE BENCHMARKING
    • TABLE 221 FOOTPRINT ANALYSIS OF COMPANIES IN DIGITAL PATHOLOGY MARKET
    • TABLE 222 PRODUCT FOOTPRINT ANALYSIS OF COMPANIES
    • TABLE 223 APPLICATION FOOTPRINT ANALYSIS OF COMPANIES
    • TABLE 224 END-USER FOOTPRINT ANALYSIS OF COMPANIES
    • TABLE 225 REGIONAL FOOTPRINT ANALYSIS OF COMPANIES
  • 11.5 COMPANY EVALUATION QUADRANT FOR KEY PLAYERS
    • 11.5.1 STARS
    • 11.5.2 EMERGING LEADERS
    • 11.5.3 PERVASIVE PLAYERS
    • 11.5.4 PARTICIPANTS
    • FIGURE 38 DIGITAL PATHOLOGY MARKET: COMPANY EVALUATION QUADRANT FOR KEY PLAYERS (2022)
  • 11.6 COMPANY EVALUATION QUADRANT FOR SMES/STARTUPS
    • 11.6.1 PROGRESSIVE COMPANIES
    • 11.6.2 DYNAMIC COMPANIES
    • 11.6.3 STARTING BLOCKS
    • 11.6.4 RESPONSIVE COMPANIES
    • FIGURE 39 DIGITAL PATHOLOGY MARKET: COMPANY EVALUATION QUADRANT FOR SMES/ STARTUPS (2022)
  • 11.7 MARKET SHARE ANALYSIS
    • FIGURE 40 DIGITAL PATHOLOGY MARKET SHARE ANALYSIS, BY KEY PLAYER, 2022
    • TABLE 226 DIGITAL PATHOLOGY MARKET: DEGREE OF COMPETITION
  • 11.8 COMPETITIVE SCENARIO
    • 11.8.1 PRODUCT LAUNCHES AND APPROVALS
    • TABLE 227 KEY PRODUCT LAUNCHES AND APPROVALS
    • 11.8.2 DEALS
    • TABLE 228 KEY DEALS

12 COMPANY PROFILES

  • 12.1 KEY PLAYERS
  • (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
    • 12.1.1 DANAHER CORPORATION
    • TABLE 229 DANAHER CORPORATION: BUSINESS OVERVIEW
    • FIGURE 41 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
    • 12.1.2 KONINKLIJKE PHILIPS N.V.
    • TABLE 230 KONINKLIJKE PHILIPS N.V.: BUSINESS OVERVIEW
    • FIGURE 42 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2022)
    • 12.1.3 HAMAMATSU PHOTONICS K.K.
    • TABLE 231 HAMAMATSU PHOTONICS K.K.: BUSINESS OVERVIEW
    • FIGURE 43 HAMAMATSU PHOTONICS K.K.: COMPANY SNAPSHOT (2022)
    • 12.1.4 F. HOFFMANN-LA ROCHE LTD.
    • TABLE 232 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
    • FIGURE 44 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
    • 12.1.5 SECTRA AB
    • TABLE 233 SECTRA AB: BUSINESS OVERVIEW
    • FIGURE 45 SECTRA AB: COMPANY SNAPSHOT (2021)
    • 12.1.6 AKOYA BIOSCIENCES, INC.
    • TABLE 234 AKOYA BIOSCIENCES, INC.: BUSINESS OVERVIEW
    • FIGURE 46 AKOYA BIOSCIENCES, INC.: COMPANY SNAPSHOT (2022)
    • 12.1.7 3DHISTECH LTD.
    • TABLE 235 3DHISTECH LTD.: BUSINESS OVERVIEW
    • 12.1.8 APOLLO ENTERPRISE IMAGING CORP.
    • TABLE 236 APOLLO ENTERPRISE IMAGING CORP.: BUSINESS OVERVIEW
    • 12.1.9 XIFIN, INC.
    • TABLE 237 XIFIN, INC.: BUSINESS OVERVIEW
    • 12.1.10 HURON DIGITAL PATHOLOGY
    • TABLE 238 HURON DIGITAL PATHOLOGY: BUSINESS OVERVIEW
    • 12.1.11 HOLOGIC, INC.
    • TABLE 239 HOLOGIC, INC.: BUSINESS OVERVIEW
    • FIGURE 47 HOLOGIC, INC.: COMPANY SNAPSHOT (2022)
    • 12.1.12 CORISTA
    • TABLE 240 CORISTA: BUSINESS OVERVIEW
    • 12.1.13 INDICA LABS INC.
    • TABLE 241 INDICA LABS INC.: BUSINESS OVERVIEW
    • 12.1.14 OBJECTIVE PATHOLOGY SERVICES LIMITED
    • TABLE 242 OBJECTIVE PATHOLOGY SERVICES LIMITED: BUSINESS OVERVIEW
    • 12.1.15 OPTRASCAN INC.
    • TABLE 243 OPTRASCAN INC.: BUSINESS OVERVIEW
    • 12.1.16 GLENCOE SOFTWARE, INC.
    • TABLE 244 GLENCOE SOFTWARE, INC.: BUSINESS OVERVIEW
    • 12.1.17 AIFORIA TECHNOLOGIES OYJ
    • TABLE 245 AIFORIA TECHNOLOGIES OYJ: BUSINESS OVERVIEW
    • 12.1.18 PAIGE AI, INC.
    • TABLE 246 PAIGE AI, INC.: BUSINESS OVERVIEW
    • 12.1.19 FUJIFILM HOLDINGS CORPORATION
    • TABLE 247 FUJIFILM HOLDINGS CORPORATION: BUSINESS OVERVIEW
    • FIGURE 48 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2021)
    • 12.1.20 PROSCIA INC.
    • TABLE 248 PROSCIA, INC.: BUSINESS OVERVIEW
  • 12.2 OTHER PLAYERS
    • 12.2.1 PATHAI, INC.
    • 12.2.2 KONFOONG BIOTECH INTERNATIONAL CO., LTD.
    • 12.2.3 MIKROSCAN TECHNOLOGIES, INC.
    • 12.2.4 MOTIC DIGITAL PATHOLOGY
    • 12.2.5 KANTERON SYSTEMS
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS